Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies

Alcohol and Alcoholism

Volumn 48, Issue 5, 2013, Pages 570-578

  van den Brink, Wim ^a   Aubin, Henri Jean ^b   Bladström, Anna ^c   Torup, Lars ^c   Gual, Antoni ^d   Mann, Karl ^e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Universite Paris Sud   (France)

^c H LUNDBECK A S   (Denmark)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; NALMEFENE; PLACEBO;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRINKING BEHAVIOR; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTIVATION; MULTICENTER STUDY (TOPIC); NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SCREENING; SLEEP DISORDER; VOMITING; DRUG INDUCED HEADACHE; LIVER FUNCTION; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883015520     PISSN: 07350414     EISSN: 14643502     Source Type: Journal    
DOI: 10.1093/alcalc/agt061     Document Type: Article

References (31)

1. Alonso J, Angermeyer MC, Bernert S et al. (2004) Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420:47-54.
2. American Psychiatric Association (APA) (2000): Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
3. Bart G, Schluger JH, Borg L et al. (2005) Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 30:2254-62.
4. Beich A, Thorsen T, Rollnick S. (2003) Screening in brief intervention trials targeting excessive drinkers in general practice: systematic review and meta-analysis. BMJ 327:536-42.
5. Cohen E, Feinn R, Arias A et al. (2007) Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 86:214-21.
6. Drummond C, Coulton S, James D et al. (2009) Effectiveness and cost-effectiveness of a stepped care intervention for alcohol use disorders in primary care: pilot study. Br J Psychiatry 195:448-56.
7. Epstein EE, Drapkin ML, Yusko DA et al. (2005) Is alcohol assessment therapeutic? Pretreatment change in drinking among alcohol-dependent women. J Stud Alcohol 66:369-78.
8. European Medicines Agency. (2010) Guideline on the development of medicinal products for the treatment of alcohol dependence. EMA/CHMP/EWP/20097/2008. February 18, 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scienti fic_guideline/2010/03/WC500074898.pdf (4 April 2013, date last accessed).
9. European Medicines Agency - Find medicine - Selincro. Available at: http://www.ema.europa.eu/ema/index.jsp?Curl=pages/medicines/human/medicines/002583/human_med_001620.jsp&mid=WC0b 01ac058001d124 (4 April 2013, date last accessed).
10. Gual A, He Y, Torup L et al. (2013) A randomised, double-blind, placebo controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol (Epub ahead of print). doi: 10.1016/j.euroneuro.2013.02.006.
11. Guy W (ed). (1976) ECDEU Assessment Manual for psychopharmacology. Publication No. 76-338. Rockville: National Institute of Mental Health.
12. Heather N, Adamson SJ, Raistrick D et al. UKATT Research Team. (2010) Initial preference for drinking goal in the treatment of alcohol problems: I. Baseline differences between abstinence and non-abstinence groups. Alcohol Alcohol 45:128-35.
13. Hodgins DC, Leigh G, Milne R et al. (1997) Drinking goal selection in behavioral self-management treatment of chronic alcoholics. Addict Behav 22:247-55.
14. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. (1996) ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice E6 (R1). June 10, 1996. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_ R1/Step4/E6_R1__Guideline.pdf (4 April 2013, date last accessed).
15. Johnson BA, Ait-Daoud N, Bowden CL et al. (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677-85.
16. Joosten EAG, Fuentes-Merillas L, de Weert GH et al. (2008) Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 77:219-26.
17. Kaner EF, Dickinson HO, Beyer F et al. (2009) The effectiveness of brief alcohol interventions in primary care settings: a systematic review. Drug Alcohol Rev 28:301-23.
18. Lecrubier Y, Sheehan DV, Weiller E et al. (1997) The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12:224-31.
19. Leucht S, Hierl S, Kissling W et al. (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 200:97-106.
20. Litten RZ, Fertig JB, Falk DE et al. (2012) A double-blind, placebo controlled trial to assess the efficacy of Quetiapine Fumarate XR in very heavy-drinking alcohol dependent patients. Alcohol Clin Exp Res 36:406-16.
21. Little R, Yau L. (1996) Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 52:1324-33.
22. Maisel NC, Blodgett JC, Wilbourne PL et al. (2013) Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 108:275-93.
23. Mann K, Lemenager T, Hoffmann S et al. (2012) Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol (Epub ahead of print). doi: 10.1111/adb.12012.
24. Mann K, Bladström A, Torup L et al. (2013) Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 73:706-13.
25. McQueen J, Howe TE, Allan L et al. (2011) Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev 10:CD005191.
26. Perestelo-Perez L, Gonzalez-Lorenzo M, Perez-Ramos J et al. (2011) Patient involvement and shared decision-making in mental health care. Curr Clin Pharmacol 6:83-90.
27. Sobell LC, Sobell MB. (1992) Timeline Follow-back: a technique for assessing self-reported ethanol consumption. In Litten RZ, Allen JP (eds). Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa: Humana Press. 41-72.
28. Sobell MB, Sobell LC. (2000) Stepped care as a heuristic approach to the treatment of alcohol problems. J Consult Clin Psychol 68:573-9.
29. Starosta AN, Leeman RF, Volpicelli JR. (2006) The BRENDA Model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract 12:80-9.
30. World Health Organization (WHO). (2000) International Guide for Monitoring Alcohol Consumption and Related Harm. WHO/MSD/MSB/00.4. 2000. Available at: http://whqlibdoc.who.int/hq/2000/who_msd_msb_00.4.pdf (4 April 2013, date last accessed).
31. World Medical Association (WMA). (2008) WMA Declaration of Helsinki: Ethical principles for medical research involving human subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/(4 April 2013, date last accessed).